Zacks Research Issues Positive Estimate for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of $1.08 for the quarter, up from their prior forecast of $1.06. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.71 EPS and FY2026 earnings at $5.96 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%.

Several other analysts have also recently commented on HALO. Benchmark restated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Up 2.0 %

Shares of NASDAQ:HALO opened at $62.27 on Friday. The stock has a market cap of $7.67 billion, a P/E ratio of 18.15, a P/E/G ratio of 0.42 and a beta of 1.32. The firm has a fifty day moving average price of $57.05 and a 200 day moving average price of $54.70. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics has a 1-year low of $37.73 and a 1-year high of $65.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $69,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $1,886,000. Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares in the last quarter. Retirement Systems of Alabama lifted its position in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. Finally, South Street Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $9,812,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.